Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C7H9F2NO2.ClH |
Molecular Weight | 213.61 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.N[C@H]1C[C@H](CC1=C(F)F)C(O)=O
InChI
InChIKey=PGVAKHBXGXBOSB-WINKWTMZSA-N
InChI=1S/C7H9F2NO2.ClH/c8-6(9)4-1-3(7(11)12)2-5(4)10;/h3,5H,1-2,10H2,(H,11,12);1H/t3-,5-;/m0./s1
Molecular Formula | C7H9F2NO2 |
Molecular Weight | 177.1487 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
CPP-115 is a gamma-aminobutyric acid aminotransferase activator, developed by Catalyst Pharmaceutical Partners, Inc. The compound does not exhibit other GABAergic or off-target activities and is rapidly and completely orally absorbed and eliminated. In rats, CPP-115 produced inhibition of cocaine-induced increases in extracellular dopamine and in synaptic dopamine in the nucleus accumbens. CPP-115 decreased spasms in the multiple-hit rat model of infantile spasms. CPP-115 was found to have high therapeutic potential for the treatment of cocaine addiction and for a variety of epilepsies, has successfully completed a Phase I safety clinical trial, and was found to be effective in the treatment of infantile spasms (West syndrome).
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:01:51 GMT 2023
by
admin
on
Sat Dec 16 02:01:51 GMT 2023
|
Record UNII |
0285I2MVUA
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
300410
Created by
admin on Sat Dec 16 02:01:51 GMT 2023 , Edited by admin on Sat Dec 16 02:01:51 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
760947-97-5
Created by
admin on Sat Dec 16 02:01:51 GMT 2023 , Edited by admin on Sat Dec 16 02:01:51 GMT 2023
|
PRIMARY | |||
|
SUB195630
Created by
admin on Sat Dec 16 02:01:51 GMT 2023 , Edited by admin on Sat Dec 16 02:01:51 GMT 2023
|
PRIMARY | |||
|
100000181849
Created by
admin on Sat Dec 16 02:01:51 GMT 2023 , Edited by admin on Sat Dec 16 02:01:51 GMT 2023
|
PRIMARY | |||
|
EU/3/12/953
Created by
admin on Sat Dec 16 02:01:51 GMT 2023 , Edited by admin on Sat Dec 16 02:01:51 GMT 2023
|
PRIMARY | |||
|
DTXSID70226977
Created by
admin on Sat Dec 16 02:01:51 GMT 2023 , Edited by admin on Sat Dec 16 02:01:51 GMT 2023
|
PRIMARY | |||
|
71252718
Created by
admin on Sat Dec 16 02:01:51 GMT 2023 , Edited by admin on Sat Dec 16 02:01:51 GMT 2023
|
PRIMARY | |||
|
0285I2MVUA
Created by
admin on Sat Dec 16 02:01:51 GMT 2023 , Edited by admin on Sat Dec 16 02:01:51 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |